Gracell Revs FasTCar To Catch Big Pharma Rivals In Myeloma
Biotech Aims To Cut CAR-T Times To 12 Days
The Chinese company’s share price has trebled in the last month thanks to impressive data at ASCO and EHA, but Gracell will need to burn rubber to close in on the frontrunners.
